Harvey Capital Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-2,000
Closed -$307K 84
2023
Q1
$307K Hold
2,000
0.12% 70
2022
Q4
$359K Hold
2,000
0.15% 64
2022
Q3
$236K Hold
2,000
0.1% 71
2022
Q2
$285K Hold
2,000
0.11% 68
2022
Q1
$344K Hold
2,000
0.11% 67
2021
Q4
$507K Hold
2,000
0.16% 63
2021
Q3
$769K Hold
2,000
0.26% 53
2021
Q2
$469K Buy
+2,000
New +$357K 0.15% 63

Other funds holding MRNA

Harvey Capital Management's MRNA Position: Q2 2023 in Review

Harvey Capital Management sold out of Moderna (MRNA) in Q2 2023, closing a stake of 2,000 shares — an estimated $307K sold.

Harvey Capital Management first reported a position in MRNA in Q2 2021 and held it in 8 quarters. The position peaked at $769K in Q3 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Harvey Capital Management reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Harvey Capital Management sold 2,000 Moderna shares in Q2 2023, an estimated $307K.
  • Harvey Capital Management first reported a position in Moderna in Q2 2021 and held it in 8 quarters.
  • Harvey Capital Management's Moderna position peaked at $769K in Q3 2021.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Harvey Capital Management's 13F filing for Q2 2023, filed 4 Aug 2023.